Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
复制标题
DOI：
10.1177/1479164115570301
复制
发表时间：
2015-05-01
影响因子：
2.4
通讯作者：
Woerle, Hans-Juergen
中科院分区：
文献类型：
--
作者：
Marx, Nikolaus;Rosenstock, Julio;Woerle, Hans-Juergen
利格列汀与格列美脲治疗2型糖尿病的心血管结局试验（NCT 01243424）是一项正在早期2型糖尿病和心血管风险增加或已确定并发症受试者中进行的随机试验，将确定利格列汀与磺脲类药物格列美脲相比的长期心血管影响。合格的患者为未接受过磺脲类药物治疗且HbA（1c）6.5%-8.5%或既往暴露于磺脲类药物（单药治疗或联合治疗方案
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular impact of linagliptin versus the sulphonylurea glimepiride. Eligible patients were sulphonylurea-naive with HbA(1c) 6.5%-8.5% or previously exposed to sulphonylurea (in monotherapy or in a combination regimen